Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) for pre‐exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB‐LA pharmacokinetics in pregnant women during the blinded period of HPTN 084. Methods Participants were randomized 1:1 to...

Full description

Saved in:
Bibliographic Details
Main Authors: Sinead Delany‐Moretlwe, Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Patricia Ntege Nahirya, Juliet Mpendo, Muchaneta Bhondai‐Mhuri, Nyaradzo Mgodi, Rebecca Berhanu, Jennifer Farrior, Estelle Piwowar‐Manning, Susan L. Ford, Craig W. Hendrix, Alex R. Rinehart, James F. Rooney, Adeola Adeyeye, Raphael J. Landovitz, Myron S. Cohen, Mina C. Hosseinipour, Mark A. Marzinke, the HPTN 084 Study Team
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Journal of the International AIDS Society
Subjects:
cabotegravir
HIV prevention
long‐acting
PrEP
pregnancy
women
Online Access:https://doi.org/10.1002/jia2.26401
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jia2.26401

Similar Items